Posters

Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis
Secukinumab Patient-PROs
Secukinumab Demographics and Characteristics

Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry

Summary:
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile •The CorronaPsoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US •Psoriasis can have significant burden on quality of life, and it is estimated that between 30–42% of patients with psoriasis have concurrent PsA •This presentation describes patient reported outcomes (PROs) in psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment
Authors:
AB Gottlieb, B Strober, AW Armstrong, JD Greenberg, C Karki, M Mason, N Guo, I Gilloteau, A Guana, M Lebwohl
PDF icon Download (524.47 KB)

Secukinumab Patient-Reported Outcomes in the Corrona Psoriasis Registry

Summary:
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, was approved for moderate to severe plaque psoriasis in 2015 •The Corrona Psoriasis Registry was launched in April 2015 in collaboration with the National Psoriasis Foundation (NPF) to study the comparative safety of approved systemic psoriasis therapies in a real world setting •Psoriasis can have significant burden on quality of life and this presentation describes patient reported outcomes (PROs) at enrollment in patients treated with secukinumab compared with other systemic treatments
Authors:
B Strober, AW Armstrong, JD Greenberg, C Karki, M Mason, N Guo, V Herrera, I Gilloteau, A Guana, M Lebwohl
PDF icon Download (485.74 KB)

Secukinumab Patient Demographics and Disease Characteristics in the Corrona Psoriasis Registry

Summary:
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, was approved for moderate to severe plaque psoriasis in 2015 •The Corrona Psoriasis Registry was launched in April 2015 in collaboration with the National Psoriasis Foundation (NPF) to study the comparative safety of approved systemic psoriasis therapies in a real world setting •This study describes the characteristics at enrollment of patients treated with secukinumab compared to those receiving other systemic treatments
Authors:
Bruce Strober, Vivian Herrera, Peter Hur, Chitra Karki, Marc Mason, Kimberly Siu, Adriana Guana, Jeffrey D Greenberg, Mark Lebwohl
PDF icon Download (497.12 KB)

Pages